Research library
Publications
The peer-reviewed publications cited across our compound profiles. Each citation is checked against the publisher or PubMed record before it is marked verified.
Verified citations 0
No references have been published for this entry yet.
Citations pending verification 27
These references have been entered but not yet confirmed. They should not be relied upon until they are marked verified.
[1]Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine (2023).
Human clinical Citation pendingPhase 2; investigational product.
[2]Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine (2022).
Human clinical Citation pendingSURMOUNT-1; licensed product.
[3]Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology (2021).
Review Citation pending[4]Wilding JPH, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine (2021).
Human clinical Citation pendingSTEP 1; randomised, placebo-controlled; licensed product.
[5]Frías JP, Davies MJ, Rosenstock J, et al.. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine (2021).
Human clinical Citation pendingSURPASS-2; licensed product.
[6]Kingsberg SA, Clayton AH, Portman D, et al.. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstetrics & Gynecology (2019).
Human clinical Citation pendingRECONNECT; licensed product.
[7]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences (2018).
Review Citation pendingReview; the authors have commercial interests in GHK-Cu.
[8]Sikiric P, Seiwerth S, Rucman R, et al.. Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications. Current Neuropharmacology (2016).
Review Citation pendingReview from the originating research group.
[9]Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine (2016).
Human clinical Citation pendingSUSTAIN-6; randomised, placebo-controlled; licensed product.
[10]Lee C, Zeng J, Drew BG, et al.. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism (2015).
Preclinical Citation pending[11]Sikiric P, Seiwerth S, Rucman R, et al.. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design (2011).
Review Citation pendingReview of preclinical gastrointestinal models.
[12]Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology (2011).
Preclinical Citation pendingRat tendon explant and fibroblast study.
[13]Forman HJ, Zhang H, Rinna A. Glutathione: overview of its protective roles, measurement, and biosynthesis. Molecular Aspects of Medicine (2009).
Review Citation pending[14]Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008).
Preclinical Citation pending[15]Chihara K, Shimatsu A, Hizuka N, et al.. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. European Journal of Endocrinology (2007).
Human clinical Citation pendingNo link publishedCompound: GHRP-2Diagnostic-use study in Japan. DOI/PMID to be added by an administrator after locating the record.
[16]Falutz J, Allas S, Blot K, et al.. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine (2007).
Human clinical Citation pendingPhase 3; licensed product (tesamorelin, TH9507).
[17]Dürr UHN, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta — Biomembranes (2006).
Review Citation pending[18]Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. Journal of Clinical Endocrinology & Metabolism (2006).
Human clinical Citation pendingPhase 1 in healthy adults; concerns CJC-1295 WITH DAC.
[19]Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?. Clinical Interventions in Aging (2006).
Review Citation pending[20]Dhillo WS, Chaudhri OB, Patterson M, et al.. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism (2005).
Human clinical Citation pendingHuman physiology study of kisspeptin-54 (not KP-10).
[21]Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine (2005).
Review Citation pending[22]Bock-Marquette I, Saxena A, White MD, DiMaio JM, Srivastava D. Thymosin β4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature (2004).
Preclinical Citation pendingMouse myocardial infarction model and cell studies.
[23]Ng FM, Sun J, Sharma L, Libinaki R, Jiang WJ, Gianello R. Metabolic studies of a synthetic lipolytic domain of growth hormone. Hormone Research (2000).
Preclinical Citation pending[24]Raun K, Hansen BS, Johansen NL, et al.. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology (1998).
Preclinical Citation pendingOriginal pharmacological characterisation (in-vitro and animal).
[25]Dorr RT, Lines R, Levine N, et al.. Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences (1996).
Human clinical Citation pendingSmall phase 1 pilot in healthy volunteers.
[26]Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology (1984).
Preclinical Citation pendingOriginal description.
[27]Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences (1977).
Preclinical Citation pendingOriginal isolation and characterisation (rabbit).
Know of a relevant publication we have not cited? Suggest it to our editorial team.